{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:34:07Z","timestamp":1793259247661,"version":"4.5.0"},"reference-count":35,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13314","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:28:31Z","timestamp":1790141311000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Tislelizumab\u2011induced psoriasis in a patient with hepatocellular carcinoma: A case report"],"prefix":"10.3892","volume":"32","author":[{"given":"Zhaochen","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, 904 Hospital of People's Liberation Army Joint Logistic Support Force, Wuxi, Jiangsu 214000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeliang","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, 904 Hospital of PLA Joint Logistic Support Force, Wuxi, Jiangsu 214000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"key20261029091509_b1-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20261029091509_b2-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"issue":"e000437","key":"key20261029091509_b3-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: An open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20261029091509_b4-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: The RATIONALE-301 phase 3 randomized clinical trial","volume":"9","author":"Finn","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1167975","key":"key20261029091509_b5-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: A review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"key20261029091509_b6-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"e45550","key":"key20261029091509_b7-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045550","article-title":"Radiation-triggered psoriasiform rash with systemic dissemination after prolonged PD-1 inhibitor therapy: A case report","volume":"104","author":"Wu","year":"2025","journal-title":"Medicine (Batimore)"},{"key":"key20261029091509_b8-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20261029091509_b9-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2009.12.054","article-title":"A review of phototherapy protocols for psoriasis treatment","volume":"64","author":"Lapolla","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key20261029091509_b10-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.0906-6705.2004.00246.x","article-title":"Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23","volume":"13","author":"Piskin","year":"2004","journal-title":"Exp Dermatol"},{"key":"key20261029091509_b11-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0261-5614(02)00214-5","article-title":"Nutritional risk screening (NRS 2002): A new method based on an analysis of controlled clinical trials","volume":"22","author":"Kondrup","year":"2003","journal-title":"Clin Nutr"},{"key":"key20261029091509_b12-ETM-32-5-13314","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20261029091509_b13-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of dverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key20261029091509_b14-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40257-017-0275-z","article-title":"Cutaneous manifestations of diabetes mellitus: A review","volume":"18","author":"Lima","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"key20261029091509_b15-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s00125-022-05710-9","article-title":"Insulin allergy: A diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study","volume":"65","author":"Sola-Gazagnes","year":"2022","journal-title":"Diabetologia"},{"key":"key20261029091509_b16-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-Based management of hepatocellular carcinoma: Systematic review and meta-analysis of randomized controlled trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"issue":"e31183","key":"key20261029091509_b17-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031183","article-title":"Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis","volume":"101","author":"Ren","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"key20261029091509_b18-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jaad.2023.09.070","article-title":"Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review","volume":"90","author":"Tarafdar","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"key20261029091509_b19-ETM-32-5-13314","first-page":"1881","article-title":"Cutaneous immune-related adverse events from immune checkpoint inhibitors: A comprehensive systematic review of 15,340 patients","volume":"39","author":"Potekaev","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20261029091509_b20-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/15563650.2013.811588","article-title":"Misuse of the Naranjo Adverse Drug Reaction Probability Scale in toxicology","volume":"51","author":"Seger","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"key":"key20261029091509_b21-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/cmi.2014.119","article-title":"Hepatitis C virus core protein triggers expansion and activation of CD4+CD25+ regulatory T cells in chronic hepatitis C patients","volume":"12","author":"Zhai","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"key20261029091509_b22-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/ddg.12677","article-title":"T-cell plasticity in inflammatory skin diseases-the good, the bad, and the chameleons","volume":"7","author":"Gatzka","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"key20261029091509_b23-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1147513","key":"key20261029091509_b24-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors","volume":"4","author":"Muhaj","year":"2023","journal-title":"Front Allergy"},{"issue":"373","key":"key20261029091509_b25-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60030373","article-title":"Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice","volume":"60","author":"Popa","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"311","key":"key20261029091509_b26-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13897","article-title":"Psoriasis induced by first-line pembrolizumab in metastatic non-small cell lung cancer: A case report","volume":"26","author":"Gatti","year":"2023","journal-title":"Oncol Lett"},{"issue":"1596818","key":"key20261029091509_b27-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1596818","article-title":"Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: A case report","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"issue":"1647297","key":"key20261029091509_b28-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1647297","article-title":"Psoriasis caused by Camrelizumab in a patient with esophageal cancer: A case report","volume":"12","author":"Duan","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"e003066","key":"key20261029091509_b29-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"88","key":"key20261029091509_b30-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010088","article-title":"Immune checkpoint inhibitor-associated cutaneous adverse events: mechanisms of occurrence","volume":"1","author":"Eshaq","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20261029091509_b31-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","article-title":"Tumor antigen-specific T helper cells in cancer immunity and immunotherapy","volume":"54","author":"Knutson","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"key20261029091509_b32-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11684-019-0735-3","article-title":"Advances on immune-related adverse events associated with immune checkpoint inhibitors","volume":"15","author":"Fan","year":"2021","journal-title":"Front Med"},{"key":"key20261029091509_b33-ETM-32-5-13314","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.3760\/cma.j.cn112137-20240112-00091","article-title":"Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)","volume":"20","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"e13626","key":"key20261029091509_b34-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13626","article-title":"NB-UVB irradiation attenuates inflammatory response in psoriasis","volume":"33","author":"Ye","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4384","key":"key20261029091509_b35-ETM-32-5-13314","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31610-y","article-title":"Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques","volume":"13","author":"Boonpethkaew","year":"2023","journal-title":"Sci Rep"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:15:16Z","timestamp":1793258116000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13314","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}